21:33 , May 11, 2018 |  BioCentury  |  Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline. On...
17:56 , May 11, 2018 |  BC Week In Review  |  Company News

Luye acquires AstraZeneca antipsychoitic for $538M

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China,...
16:13 , May 7, 2018 |  BC Extra  |  Company News

Luye paying AZ $538M for antipsychotic

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China,...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
20:43 , Apr 27, 2018 |  BioCentury  |  Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
20:11 , Apr 26, 2018 |  BC Innovations  |  Translation in Brief

Modulating metabolism in MS

Johns Hopkins University researchers showed in Science Tecfidera dimethyl fumarate blocks aerobic glycolysis by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH), shedding light on how the multiple sclerosis drug suppresses immune activation and suggesting metabolism as a target...
21:16 , Apr 24, 2018 |  BC Extra  |  Company News

Biogen looks to ex-U.S. markets for growth

Biogen Inc. (NASDAQ:BIIB) perceives greater long-term growth opportunities than anticipated in the EU and emerging markets, the company's CEO Michel Vounatsos said on its earnings call Tuesday, while noting that the U.S. market remains its...
17:45 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...
17:15 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Merck's evobrutinib meets in Phase IIb for MS

Merck KGaA (Xetra:MRK) said evobrutinib (M2951, MSC2364447C) met the primary endpoints of reducing the total number of gadolinium-enhancing T1 lesions from baseline to weeks 12, 16, 20 and 24 vs. placebo in a Phase IIb...
21:34 , Feb 28, 2018 |  BC Extra  |  Financial News

Celgene's slide continues after refusal to file letter

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063) to treat multiple sclerosis. The news was announced after market close Tuesday...